AVXL
Anavex Life Sciences Corp. NASDAQ Listed Aug 2, 2006$3.12
Mkt Cap $289.6M
52w Low $2.61
4.5% of range
52w High $13.99
50d MA $3.74
200d MA $6.18
P/E (TTM)
-6.2x
EV/EBITDA
-14.2x
P/B
3.0x
Debt/Equity
0.0x
ROE
-31.6%
P/FCF
-19.4x
RSI (14)
—
ATR (14)
—
Beta
1.18
50d MA
$3.74
200d MA
$6.18
Avg Volume
1.5M
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
51 West 52nd Street · New York City, NY 10019 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | AMC | -0.10 | -0.06 | +40.0% | 4.35 | -0.2% | -9.0% | -10.8% | -9.9% | -9.7% | -7.1% | — |
| Nov 25, 2025 | AMC | -0.13 | -0.11 | +15.4% | 3.46 | +2.6% | +11.6% | +10.7% | +10.4% | +6.1% | +32.1% | — |
| Aug 12, 2025 | AMC | -0.13 | -0.16 | -23.1% | 10.78 | -0.3% | -2.0% | -6.2% | -7.7% | -11.0% | -12.4% | — |
| May 13, 2025 | AMC | -0.16 | -0.13 | +18.8% | 8.12 | +1.6% | +0.6% | +3.1% | +2.5% | +3.9% | -7.3% | — |
| Feb 12, 2025 | AMC | -0.17 | -0.14 | +17.6% | 8.70 | +0.0% | -2.6% | -2.1% | +0.0% | +0.2% | -0.2% | — |
| Dec 23, 2024 | AMC | -0.17 | -0.14 | +17.6% | 11.18 | +3.0% | -2.8% | +12.3% | +8.3% | -1.3% | -3.9% | — |
| Aug 6, 2024 | AMC | -0.15 | -0.14 | +6.7% | 6.82 | +2.6% | -10.9% | -2.6% | -7.5% | -9.7% | -5.9% | — |
| May 9, 2024 | AMC | -0.13 | -0.13 | +0.0% | 3.88 | +0.0% | -1.8% | +2.8% | +11.1% | +15.7% | +16.0% | — |
| Feb 7, 2024 | AMC | -0.15 | -0.11 | +26.7% | 5.59 | +1.3% | +1.8% | +3.4% | +9.8% | -0.2% | +4.5% | — |
| Nov 27, 2023 | AMC | -0.16 | -0.12 | +25.0% | 6.36 | +2.7% | +6.6% | +11.5% | +13.4% | +19.0% | +28.9% | — |
| Aug 8, 2023 | AMC | -0.17 | -0.14 | +17.6% | 8.03 | +1.2% | +16.7% | +12.7% | +9.8% | +13.9% | +11.3% | — |
| May 9, 2023 | AMC | -0.18 | -0.17 | +5.6% | 9.07 | +2.8% | +3.2% | +1.3% | +0.3% | +4.6% | -0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | Rodman & Renshaw | Initiates | Buy | $20 | $3.32 | $3.35 | +0.9% | +2.7% | +1.2% | +0.6% | -6.0% | — |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $2.82 | $2.85 | +1.1% | +8.9% | +9.9% | +6.0% | +5.0% | +9.2% |
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $2.74 | $2.71 | -1.1% | +5.1% | +2.9% | +2.9% | +12.0% | +13.1% |
| Mar 23 | D. Boral Capital | Maintains | Buy → Buy | — | $4.06 | $4.10 | +1.0% | +9.4% | +3.2% | -32.5% | -29.1% | -30.5% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.35 | $4.34 | -0.2% | -9.0% | -10.8% | -9.9% | -9.7% | -7.1% |
| Feb 9 | D. Boral Capital | Maintains | Buy → Buy | — | $4.10 | $4.20 | +2.4% | +6.1% | -3.4% | -5.4% | -4.4% | -4.1% |
| Jan 6 | D. Boral Capital | Maintains | Buy → Buy | — | $3.95 | $4.13 | +4.6% | +1.5% | +3.8% | +8.1% | +8.4% | +8.6% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.89 | $3.90 | +0.3% | -5.7% | -3.6% | -4.1% | -4.4% | -6.4% |
| Dec 19 | D. Boral Capital | Maintains | Buy → Buy | — | $3.89 | $3.90 | +0.3% | -5.7% | -3.6% | -4.1% | -4.4% | -6.4% |
| Dec 15 | D. Boral Capital | Maintains | Buy → Buy | — | $4.02 | $3.93 | -2.2% | +3.0% | +0.0% | -2.5% | -3.2% | -8.7% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.86 | $3.93 | +1.8% | -0.8% | -1.0% | -4.9% | +18.4% | +15.3% |
| Nov 26 | D. Boral Capital | Maintains | Buy → Buy | — | $3.46 | $3.55 | +2.6% | +11.6% | +10.7% | +10.4% | +6.1% | +32.1% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.50 | $3.47 | -0.9% | +2.9% | -9.4% | -6.9% | -12.0% | -1.1% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $5.69 | $2.96 | -48.0% | -35.9% | -37.1% | -38.5% | -36.7% | -44.3% |
| Oct 29 | D. Boral Capital | Maintains | Buy → Buy | — | $8.10 | $8.10 | +0.0% | -1.0% | -0.9% | -1.6% | -4.4% | -7.8% |
| Oct 24 | Jones Trading | Downgrade | Buy → Hold | — | $8.74 | $8.81 | +0.8% | -1.4% | -2.9% | -7.3% | -8.2% | -8.1% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.61 | $9.65 | +0.4% | +1.8% | +2.5% | -0.9% | -3.5% | -10.3% |
| Oct 2 | D. Boral Capital | Maintains | Buy → Buy | — | $9.01 | $9.19 | +2.0% | +1.3% | +10.5% | +6.7% | +8.5% | +9.3% |
| Oct 1 | D. Boral Capital | Maintains | Buy → Buy | — | $8.90 | $8.92 | +0.2% | +1.2% | +2.6% | +11.9% | +8.0% | +9.9% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.26 | $10.28 | +0.2% | -13.5% | -6.6% | -8.7% | -11.4% | -12.7% |
| Sep 10 | D. Boral Capital | Maintains | Buy → Buy | — | $10.26 | $10.28 | +0.2% | -13.5% | -6.6% | -8.7% | -11.4% | -12.7% |
| Aug 27 | D. Boral Capital | Maintains | Buy → Buy | — | $9.53 | $9.37 | -1.7% | -0.8% | -3.3% | +1.2% | -0.5% | -0.2% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.55 | $9.50 | -0.5% | -0.2% | -1.6% | -0.2% | -1.0% | -3.5% |
| Aug 13 | D. Boral Capital | Maintains | Buy → Buy | — | $10.78 | $10.75 | -0.3% | -2.0% | -6.2% | -7.7% | -11.0% | -12.4% |
| Aug 4 | D. Boral Capital | Maintains | Buy → Buy | — | $11.20 | $11.09 | -1.0% | -3.4% | -2.8% | -2.1% | +0.2% | -1.1% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.19 | $7.89 | -3.7% | +1.7% | -7.2% | +6.5% | +4.3% | +8.2% |
| Apr 7 | D. Boral Capital | Maintains | Buy → Buy | — | $8.19 | $7.89 | -3.7% | +1.7% | -7.2% | +6.5% | +4.3% | +8.2% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.72 | $8.41 | -3.6% | -1.6% | -8.0% | -1.8% | -4.8% | -6.1% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $8.54 | +0.2% | +2.1% | +2.3% | +1.9% | -2.0% | -3.1% |
| Feb 12 | D. Boral Capital | Maintains | Buy → Buy | — | $8.29 | $8.05 | -2.9% | +4.9% | +2.2% | +2.8% | +4.9% | +5.2% |
| Jan 28 | D. Boral Capital | Maintains | Buy → Buy | — | $9.82 | $9.87 | +0.5% | +0.9% | -1.2% | -2.5% | -5.6% | -12.0% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.82 | $9.87 | +0.5% | +0.9% | -1.2% | -2.5% | -5.6% | -12.0% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.21 | $9.25 | +0.4% | +6.9% | +8.5% | +10.7% | +13.9% | +6.6% |
| Jan 15 | D. Boral Capital | Maintains | Buy → Buy | — | $10.47 | $10.70 | +2.2% | +8.2% | -3.1% | -12.0% | -5.9% | -4.6% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $11.23 | $11.02 | -1.9% | -6.1% | -6.8% | +0.9% | -9.6% | -18.0% |
| Dec 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.87 | $10.84 | -0.3% | +15.5% | +11.4% | +1.6% | -1.2% | +11.8% |
| Dec 23 | D. Boral Capital | Maintains | Buy → Buy | — | $8.63 | $8.92 | +3.4% | +29.5% | +26.0% | +45.5% | +40.3% | +27.9% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.04 | $9.09 | +0.6% | -0.1% | +4.6% | +3.1% | -0.7% | +0.2% |
| Nov 26 | D. Boral Capital | Maintains | Buy → Buy | — | $9.13 | $10.30 | +12.8% | -1.0% | -1.1% | +3.6% | +2.1% | -1.6% |
| Nov 25 | D. Boral Capital | Maintains | Buy → Buy | — | $9.11 | $9.52 | +4.5% | +0.2% | -0.8% | -0.9% | +3.8% | +2.3% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.84 | $6.82 | -0.3% | +6.7% | +12.6% | +13.9% | +11.7% | +35.1% |
| Oct 31 | EF Hutton | Maintains | Buy → Buy | — | $5.71 | $5.88 | +3.0% | +15.9% | +19.8% | +27.8% | +34.9% | +36.4% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.51 | $5.52 | +0.2% | +2.5% | -1.1% | +2.4% | -2.2% | -3.3% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.80 | $6.77 | -0.4% | -3.2% | -4.4% | -5.1% | +0.3% | -10.6% |
| Jul 29 | EF Hutton | Maintains | Buy → Buy | — | $6.74 | $7.00 | +3.9% | +4.5% | -6.4% | +0.9% | -2.4% | -3.6% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.79 | $3.75 | -1.1% | -2.4% | -1.1% | -1.6% | -0.5% | -1.6% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.88 | $3.88 | +0.0% | -1.8% | +2.8% | +11.1% | +15.7% | +16.0% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.05 | $6.09 | +0.7% | +7.9% | +4.0% | -0.7% | +8.4% | +6.0% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.36 | $6.53 | +2.7% | +6.6% | +11.5% | +13.4% | +19.0% | +28.9% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.68 | $8.00 | +4.2% | +4.6% | +22.0% | +17.8% | +14.8% | +19.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Anavex Life Sciences Corp. -- 8-K 5.02: Executive Change
Anavex Life Sciences named Terrie Kellmeyer interim CEO following Christopher Missling's resignation, though Kellmeyer simultaneously resigned from the same position, creating leadership uncertainty.
May 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Anavex Life Sciences' withdrawn EMA application for blarcamesine signals regulatory setbacks that delay European market access and increase development timelines, pressuring near-term revenue prospects.
Mar 25
8-K · 5.02
!!! Very High
Anavex Life Sciences -- 8-K 5.02: Executive Change
Anavex Life Sciences appointed Axel Paeger as director effective February 23, 2026, potentially signaling leadership changes that investors should monitor for strategic implications.
Feb 25
8-K
Anavex Life Sciences -- 8-K Filing
Anavex Life Sciences reported Q1 fiscal 2026 results and provided a business update, with management hosting a webcast to discuss the clinical-stage biotech company's financial performance and strategic developments.
Feb 9
Data updated apr 24, 2026 8:05pm
· Source: massive.com